Advertisement

Topics

Dr. Reddy’s Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market

12:05 EST 27 Dec 2018 | Investing News Network

Dr. Reddy’s Laboratories (BSE:500124, NSE:DRREDDY, NYSE:RDY) announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA). As quoted in the press release: The Renvela brand and generic had … Continued

The post Dr. Reddy’s Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market appeared first on Investing News Network.

Original Article: Dr. Reddy’s Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market

NEXT ARTICLE

More From BioPortfolio on "Dr. Reddy’s Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...